Inhibitors of ATR or CHK1, such as berzosertib or prexasertib, could selectively kill POLD1-mutant tumor cells by exacerbating replication collapse, a strategy already showing promise in POLE-mutated cancers (71). The gene discussed is POLD1; the disease is neoplasm.